Literature DB >> 10932284

Plasma homocysteine and MTHFR C677T genotype in levodopa-treated patients with PD.

K Yasui1, H Kowa, K Nakaso, T Takeshima, K Nakashima.   

Abstract

Plasma homocysteine and cysteine levels were measured in 90 patients with PD with the MTHFR C677T (T/T) genotype. The authors found that the levels of homocysteine-a possible risk factor for vascular disease-were elevated by 60% in levodopa-treated patients with PD, with the most marked elevation occurring in patients with the T/T genotype. Cysteine levels in subjects with PD did not differ from levels in control subjects. In the T/T genotype patients, homocysteine and folate levels were inversely correlated. Increased homocysteine might be related to levodopa, MTHFR genotype, and folate in PD.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10932284     DOI: 10.1212/wnl.55.3.437

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  22 in total

1.  The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.

Authors:  E Nissinen; H Nissinen; H Larjonmaa; A Väänänen; T Helkamaa; I Reenilä; P Rauhala
Journal:  J Neural Transm (Vienna)       Date:  2004-12-22       Impact factor: 3.575

2.  Effect of MTHFR polymorphisms on hyperhomocysteinemia in levodopa-treated Parkinsonian patients.

Authors:  D Caccamo; G Gorgone; M Currò; G Parisi; W Di Iorio; C Menichetti; V Belcastro; L Parnetti; A Rossi; F Pisani; R Ientile; P Calabresi
Journal:  Neuromolecular Med       Date:  2007       Impact factor: 3.843

Review 3.  Will pharmacogenetics allow better prediction of methotrexate toxicity and efficacy in patients with rheumatoid arthritis?

Authors:  P Ranganathan; S Eisen; W M Yokoyama; H L McLeod
Journal:  Ann Rheum Dis       Date:  2003-01       Impact factor: 19.103

4.  Possible treatment concepts for the levodopa-related hyperhomocysteinemia.

Authors:  Thomas Müller
Journal:  Cardiovasc Psychiatry Neurol       Date:  2009-09-09

5.  Association of MTHFR C677T with total homocysteine plasma levels and susceptibility to Parkinson's disease: a meta-analysis.

Authors:  Ying Zhu; Rui-Xia Zhu; Zhi-Yi He; Xu Liu; He-Nan Liu
Journal:  Neurol Sci       Date:  2015-01-07       Impact factor: 3.307

6.  Homocysteine levels in aqueous humor and plasma of patients with primary open-angle glaucoma.

Authors:  J B Roedl; S Bleich; U Reulbach; N von Ahsen; U Schlötzer-Schrehardt; R Rejdak; G O H Naumann; F E Kruse; J Kornhuber; A G M Jünemann
Journal:  J Neural Transm (Vienna)       Date:  2006-08-24       Impact factor: 3.575

7.  The MTHFR C677T polymorphism modifies age at onset in Parkinson's disease.

Authors:  Annamaria Vallelunga; Valentina Pegoraro; Manuela Pilleri; Roberta Biundo; Angela De Iuliis; Mauro Marchetti; Silvia Facchini; Patrizia Formento Dojot; Angelo Antonini
Journal:  Neurol Sci       Date:  2013-09-20       Impact factor: 3.307

Review 8.  Carnosine and Related Peptides: Therapeutic Potential in Age-Related Disorders.

Authors:  José H Cararo; Emilio L Streck; Patricia F Schuck; Gustavo da C Ferreira
Journal:  Aging Dis       Date:  2015-10-01       Impact factor: 6.745

9.  Effect of entacapone on plasma homocysteine levels in Parkinson's disease patients.

Authors:  Martin Nevrly; Petr Kanovsky; Hana Vranova; Katerina Langova; Petr Hlustik
Journal:  Neurol Sci       Date:  2010-05-13       Impact factor: 3.307

10.  Evidence that folic acid deficiency is a major determinant of hyperhomocysteinemia in Parkinson's disease.

Authors:  Eliseu Felippe dos Santos; Estela Natacha Brandt Busanello; Anelise Miglioranza; Angela Zanatta; Alethea Gatto Barchak; Carmen Regla Vargas; Jonas Saute; Charles Rosa; Maria Júlia Carrion; Daiane Camargo; André Dalbem; Jaderson Costa da Costa; Sandro René Pinto de Sousa Miguel; Carlos Roberto de Mello Rieder; Moacir Wajner
Journal:  Metab Brain Dis       Date:  2009-03-18       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.